Literature DB >> 6601527

The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis.

D J Hinrichs, K W Wegmann, B A Peters.   

Abstract

The immunosuppressive effects of cyclosporin A (CsA) were tested on actively induced and passively transferred experimental allergic encephalomyelitis (EAE). Actively induced EAE could be inhibited if CsA was administered per os at 25 mg/kg/day but not at 10 mg/kg/day. Passive transfer of clinical EAE occurred in all cell recipients including those fed CsA at either 25 or 50 mg/kg/day. Cyclosporin A could inhibit the development of transfer active cells in vitro and in vivo, however, inhibition of transfer active populations by CsA required the presence of CsA during the initial stage of cell response. If CsA was added to Con A-stimulated spleen cell cultures after a delay of 24 hr then these cells transferred clinical disease. Similarly, animals fed CsA concurrently with basic protein sensitization did not develop cell populations capable of transferring EAE. If CsA feeding commenced 2 or 4 days following sensitization all basic protein-sensitized animals still failed to develop EAE; however these latter groups of animals were a suitable source of cells capable of transferring some signs of clinical EAE.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601527     DOI: 10.1016/0008-8749(83)90020-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus.

Authors:  W S Lane; A Galat; M W Harding; S L Schreiber
Journal:  J Protein Chem       Date:  1991-04

2.  Pharmacological comparison of active and passive experimental allergic encephalomyelitis in the rat.

Authors:  S Desai; R Barton
Journal:  Agents Actions       Date:  1989-06

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Preventive and therapeutic effects of cyclosporin and valine2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.

Authors:  C Feurer; L H Chow; J F Borel
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

5.  Effects of cyclosporin on collagen induced arthritis in mice.

Authors:  K Takagishi; N Kaibara; T Hotokebuchi; C Arita; M Morinaga; K Arai
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

6.  Effect of cyclosporin A on an experimental chronic viral infection of the central nervous system.

Authors:  O Boespflug; C Godfraind; M Tardieu
Journal:  J Neuroimmunol       Date:  1989-01       Impact factor: 3.478

7.  Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats.

Authors:  R Sorokin; H Kimura; K Schroder; D H Wilson; D B Wilson
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.